BioWorld Asia

April 15, 2009

BioXell Shares Plunge on Elocalcitol Miss

BioXell SpA suffered a collapse in its share price following news that its vitamin D3 analogue elocalcitol failed to meet the primary endpoint of a Phase IIb trial in overactive bladder (OAB). (BioWorld International) Read More

ReNeuron Able to Automate Fetal Neural Stem Cell Process

China: Through New Initiatives it Seeks to Boost Innovation

Renovo Confirms it has a Suitor Waiting in the Wings

Amarin Eyes European OK for AMR101 in Huntington's

Study Supplies Missing Piece to Antibiotic Pump Puzzle

Canada and Europe to Work Together on Medicines

Biocortech Initiates Trial of Depression Blood Test

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...